Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: October 18, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from psoriasis.

Condition Intervention Phase
Other: Tuberculin skin test and Quantiferon -TB Gold test
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • The level of agreement between TST and QTF in patients with psoriasis in comparison with controls [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • Levels of TST in patients with psoriasis in comparison with healthy controls [ Time Frame: 3 days ]

Estimated Enrollment: 150
Study Start Date: November 2010
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Tuberculin skin test and Quantiferon -TB Gold test

    TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.

    QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with psoriasis and psoriatic arthritis
  • Aged 18-90

Exclusion Criteria:

  • History of TB
  • Known allergy to TST
  • Current or past treatment with anti-TNF alpha
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01223976

Contact: Ori Elkayam, MD 97236973668
Contact: Ayelet Brill 97236974837

Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Ori Elkayam, M.D    97236973668   
Principal Investigator: Ori Elkayam         
Sub-Investigator: Hagit Mats         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

Responsible Party: Prof. Ori Elkayam, Tel Aviv Medical Center Identifier: NCT01223976     History of Changes
Other Study ID Numbers: 222-10
Study First Received: October 18, 2010
Last Updated: October 18, 2010

Keywords provided by Tel-Aviv Sourasky Medical Center:
latent tuberculosis psoriasis arthritis TST QTF
Screening of latent tuberculosis in psoriasis

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections processed this record on May 25, 2017